FARMINGDALE, N.Y., July 12, 2012 /PRNewswire/ -- Misonix, Inc. (NasdaqGM: MSON), a surgical device company that designs, manufactures and markets innovative therapeutic ultrasonic products worldwide for spine surgery, skull-based surgery, neurosurgery, wound debridement, cosmetic surgery, laparoscopic surgery and other surgical applications, has announced the addition of industry veteran, Christopher A. DeNicola, to its sales management team. Mr. DeNicola joined the Company on July 1, 2012, as Senior Director of Sales – North America for its neurosurgery, spine surgery and orthopedic surgery products. Products in this category are the SonaStar® Ultrasonic Surgical Aspiration System and the BoneScalpel™ Ultrasonic Bone Cutting System.
Mr. DeNicola, who is degreed in Management, has almost 20 years of successful sales management experience in Orthopedic Surgery, Neurosurgery and Podiatric Surgery, with a heavy concentration in Spine Surgery. He has worked with direct, distributor and hybrid sales organizations. Previous employers included EBI (a Biomet Company), Small Bone Innovations and Scient'x USA. The Company expects that Mr. DeNicola's presence will add measurably to the rapid expansion of its Neuro/Orthopedic sales organization.
The SonaStar is used by neurosurgeons and general surgeons for quick and efficient removal of both hard and soft tumors while sparing most vessels. OsteoSculpt™ bone sculpting technology can be employed with the SonaStar to safely remove osseous structures, thus providing access to the surgical site.
The BoneScalpel is a tissue specific osteotomy device capable of safely making precise cuts through bone and hard tissue while largely preserving delicate soft tissue structures. It offers the convenience and speed of a power instrument without the danger associated with rotary sharps. Use of this product is being rapidly accepted by spine and skull-based surgeons on a worldwide basis.
"We are very pleased to add a sales executive of Chris DeNicola's experience and stature to our growing domestic sales organization," said Michael A. McManus, Jr., President and Chief Executive Officer of Misonix. "His knowledge of distributors, combined with his established relationships with physician thought leaders in our target markets, should prove to be quite valuable in rapidly expanding our domestic market presence."
Misonix, Inc. designs, develops, manufactures and markets therapeutic ultrasonic medical devices. Misonix's therapeutic ultrasonic platform is the basis for several innovative medical technologies. Addressing a combined market estimated to be in excess of $3 billion annually; Misonix's proprietary ultrasonic medical devices are used for wound debridement, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications. Additional information is available on the Company's Web site at www.misonix.com.
Safe Harbor Statement
With the exception of historical information contained in this press release, content herein may contain "forward looking statements" that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated with international sales and currency fluctuations, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, the timing of finding strategic partners and implementing such relationships, regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company's business lines, and other factors discussed in the Company's Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company disclaims any obligation to update its forward-looking relationships.
SOURCE Misonix, Inc.